Comparable Ipilimumab/Nivolumab Outcomes Observed in Older RCC PopulationByAntonio Ocejo, MD March 5th 2026Although older patients saw a greater rate of AE-related discontinuations, survival outcomes were similar between groups.
Data Show Comparable Immunotherapy Outcomes Across RCC Age PopulationsByAntonio Ocejo, MD February 28th 2026Despite differences in treatment tolerance across different RCC subgroups, survival outcomes were similar in a retrospective study.